Bridgehead Global is an internationalisation programme to facilitate European health start-ups in scaling out beyond Europe. The programme’s aim is to prepare the ground for international expansion and to help start-ups achieve their first tangible business results in non-European markets. The programme follows an individual and needs-based approach by matching promising start-ups and SMEs to suitable clusters, accelerators and incubators (Global CATalysers, or Global CATs) that are based in Europe and cooperate with their own network of global partners beyond Europe.
EIT Health provides funding up to €40 000 for SMEs to work with a Global CAT who will guide the start-up and facilitate their preparation and readiness to travel to the location of their choice within EIT Health’s network of collaborators beyond-Europe, including the US, Canada, Israel, China and Japan, among others. The participants are individually supported in entering new markets with knowledge about specific countries’ healthcare systems, regulatory environments, key stakeholders and competitors. Global CATs offer Bridgehead Global start-ups structured access to vibrant eco-systems, with connections to industries, corporations, venture capital, entrepreneurs, experts, specialists and mentors.
Is it for me?
The EIT Health Bridgehead Global Programme is suitable for micro- and small enterprises (less than 50 employees) that are active in the fields of MedTech, BioTech and Digital Health, are incorporated in an H2020-eligible country, and are operating in an EU country. Applicants should have a defined product strategy, proven traction in their home market and a clear internationalisation plan for going beyond Europe.
- 30 March 2020, 23:59h CET.
Aplications and more information can be found here.